Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007
Public ClinicalTrials.gov record NCT02301234. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as adjunctive therapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.
Study identification
- NCT ID
- NCT02301234
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Fulranumab 1 mg Drug
- Fulranumab 3 mg Drug
- Celecoxib 100 mg Drug
- Celecoxib 100 mg Matching Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2015 (Actual)
- Primary completion
- Sep 19, 2016 (Actual)
- Completion
- Sep 19, 2016 (Actual)
- Last update posted
- Sep 14, 2017
2015 – 2016
United States locations
- U.S. sites
- 32
- U.S. states
- 16
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Glendale | Arizona | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Anaheim | California | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | North Hollywood | California | — | — |
| Not listed | Boulder | Colorado | — | — |
| Not listed | Coral Gables | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Columbus | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Overland Park | Kansas | — | — |
| Not listed | Elkridge | Maryland | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Norman | Oklahoma | — | — |
| Not listed | Knoxville | Tennessee | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Tullahoma | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Lampasas | Texas | — | — |
| Not listed | Nassau Bay | Texas | — | — |
| Not listed | Sugar Land | Texas | — | — |
| Not listed | Arlington | Virginia | — | — |
| Not listed | Charlottesville | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02301234, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02301234 live on ClinicalTrials.gov.